SYNHinactive

Syneos Health, Inc.

Healthcare·Oncology·Phase 1
OncologyImmunologyRespiratory

Syneos Health, Inc. (SYNH): 3 pipeline candidates · ~57 mo cash runway · 3 clinical trials. Updated within the last hour.

6.5/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway10.0

57.3 months

Financial Health6.1

D/E 1.31

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for Syneos Health, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$82.3M

Quarterly Burn

$33.7M

Runway

57.3 mo

Revenue

$1.4B

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Mar 2031
Today~63 mo out
Catalyst within runway

Pipeline (3 candidates)

3 clinical trials

Frequently asked questions

How many drug candidates are in Syneos Health, Inc.'s pipeline?

Syneos Health, Inc. (SYNH) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Syneos Health, Inc.'s lead drug candidate?

Syneos Health, Inc.'s most advanced tracked candidate is aio-001 (Phase 1) for Respiratory Disease.

What is Syneos Health, Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Syneos Health, Inc. has approximately 57.3 months of cash runway.

Get the full picture on Syneos Health, Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.